 NEW YORK , March 29, 2022 PRNewswire -- Synaptogenix, Inc. Nasdaq: SNPX Synaptogenix or the Company, an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon, the Companys President and Chief Scientific Officer, will present at the Hanson Wade 10th Annual Neurodegenerative Drug Development Summit on Tuesday, March 29 th at 2pm ET. The presentation is entitled, Bryostatin Targets Restoration of Synaptic Wiring in Alzheimers Degeneration. 